ArticleScientific reports2017
Polydatin protects the respiratory system from PM
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Polydatin for treating spinal cord injury: Multiple mechanisms and challenges.Journal of pharmaceutical analysis · 2026Review
- Polydatin in respiratory diseases: multi-target mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Synergistic Toxicity of Fine Particulate Matter and Ozone and Their Underlying Mechanisms.Toxics · 2025Review
- The Mechanism of Traditional Chinese Medicine and Natural Medicine in Treating Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Review
- Polydatin alleviates bleomycin-induced pulmonary fibrosis and alters the gut microbiota in a mouse model.Journal of cellular and molecular medicine · 2023Article
- Therapeutic Effects of Cornuside on Particulate Matter-Induced Lung Injury.International journal of molecular sciences · 2023Article
- Cirsilineol Treatment Attenuates PMInternational journal of molecular sciences · 2022Article
- Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments.PPAR research · 2022Review
- Article
- The upshot of Polyphenolic compounds on immunity amid COVID-19 pandemic and other emerging communicable diseases: An appraisal.Natural products and bioprospecting · 2020Review
- Polydatin prevents bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β/Smad/ERK signaling pathway.Experimental and therapeutic medicine · 2020Article
- Biapenem as a Novel Insight into Drug Repositioning against Particulate Matter-Induced Lung Injury.International journal of molecular sciences · 2020Article
- Polydatin Inhibits NLRP3 Inflammasome in Dry Eye Disease by Attenuating Oxidative Stress and Inhibiting the NF-κB Pathway.Nutrients · 2019Article
- Kefir peptides alleviate particulate matter <4 μm (PMScientific reports · 2019Article
- PM2.5 affects establishment of immune tolerance in newborn mice by reducing PD-L1 expression.Journal of biosciences · 2019Article
- Protective Effect ofInternational journal of molecular sciences · 2018Article
- Polydatin suppresses nucleus pulposus cell senescence, promotes matrix homeostasis and attenuates intervertebral disc degeneration in rats.Journal of cellular and molecular medicine · 2018Article
- Radiation Protection of Polydatin Against Radon Exposure Injury of Epithelial Cells and Mice.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atmospheric particle is one of the risk factors for respiratory disease; however, their injury mechanisms are poorly understood, and prevention methods are highly desirable. We constructed artificial PM
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.